Dr. Alexander Y. Rudensky is the chair of the Immunology Program and director of the Ludwig Center for Cancer Immunotherapy at the Memorial Sloan Kettering Cancer Center.
Dr. Rudensky has made important contributions in our understanding of how Foxp3 influences the development of regulatory T (Treg) cells, immune cells that can prevent autoimmunity and excessive inflammation, but can also protect cancer cells from potential immune responses. In recognition of his work, he received the 2015 William B. Coley Award for Distinguished Research in Basic Immunology and was elected to the National Academy of Sciences. In 2018, he was awarded the 2018 Vilcek Prize in Biomedical Science. He remains committed to understanding more about Treg behavior and identifying better ways to target them via immunotherapy.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. Rudensky serves on the Postdoctoral Fellowship Review Committee.
The basic research [we] are doing … is likely to have widespread clinical applications. Potential therapies that act by boosting or targeting [regulatory T cells] are now being explored for autoimmune diseases, such as diabetes and rheumatoid arthritis, as well as for cancer.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.